The downstream response to c MET activation relies on stereotypical signaling modulators widespread to many RTKs. These pathways are already reviewed in detail, and are summarized in Figure 2.
While in the con text of c MET signaling, this results in pheno types including cell proliferation, cell motility and cell cycle progression. Src homology 2 domain containing phosphatase 2 also can link c MET signaling to AG-1478 the MAPK cas cade, as sequestration of SHP2 to GAB1 is responsible for extending the duration of MAPK phosphorylation. The other major arm of c MET signaling is the PI3K/Akt signaling axis. The p85 subunit of PI3K can bind either directly to c MET or indi rectly through GAB1, which then signals through AKT/protein kinase B. This axis is primarily responsible for the cell survival response to c MET signaling .
FAK is activated through phosphorylation by SRC family kinases, which have been shown to associ ALK Inhibitor ate directly with c MET. The c MET?SRC?FAK interaction leads to cell migration and the promotion of anchorage inde pendent growth. In addition, SRC activation can positively feed back on c MET activation. Because of this, combi natorial therapies involving both c MET and SRC inhibitors show promise in the treatment of cancers dependent on either kinase. Negative regulation of the c MET receptor is crucial for its tightly controlled activity, and can occur through a number of mechanisms. The Y1003 site, located in the juxtamembrane domain, is a negative regulatory site for c MET signaling that acts by recruiting c CBL.
c MET membrane partners can then amplify and/or diversify c MET dependent biochemical inputs and translate them into meaningful biological outcomes. For instance, the v6 splice variant of the hyaluronan ALK Inhibitor receptor CD44 links c MET signaling to the actin cyto skeleton via GRB2 and the ezrin, radixin and moesin family of proteins in order to recruit SOS, which then amplifies RAS ERK sig naling.
Monday, February 18, 2013
Top 5 Most Asked Queries About AG-1478 ALK Inhibitor
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment